SNDX — Syndax Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.44bn
- $1.33bn
- $23.68m
Annual income statement for Syndax Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.52 | 140 | 0 | 0 | 23.7 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 22.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 72.9 | 113 | 152 | 230 | 363 |
| Operating Profit | -71.4 | 26.2 | -152 | -230 | -340 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -73.2 | 24.9 | -149 | -209 | -319 |
| Net Income After Taxes | -73.2 | 24.9 | -149 | -209 | -319 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -73.2 | 24.9 | -149 | -209 | -319 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -77.1 | 24.9 | -149 | -209 | -319 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.87 | 0.465 | -2.46 | -2.98 | -3.72 |